Af­ter sell­ing off Tib­so­vo and en­tire can­cer pipeline, Agios nets first ap­proval for new 'an­chor pro­duc­t'

Agios’ long-term plan is start­ing to come in­to fo­cus, as the biotech won its first FDA ap­proval since piv­ot­ing away from on­col­o­gy Thurs­day.

The FDA ap­proved Agios’ mi­tapi­vat in a rare blood dis­or­der known as pyru­vate ki­nase de­fi­cien­cy, which man­i­fests as red blood cells be­ing de­stroyed faster than they can be made. Agios won the OK in adult pa­tients and tout­ed mi­tapi­vat, to be brand­ed as Pyrukynd, as the con­di­tion’s first ap­proved dis­ease-mod­i­fy­ing ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER